A Phase III Randomized Trial With NEOadjuvant Chemotherapy (TAC) With or Without ZOledronic Acid for Patients With HER2- Negative Large Resectable or Locally Advanced Breast Cancer(NEO-ZOTAC).

Trial Profile

A Phase III Randomized Trial With NEOadjuvant Chemotherapy (TAC) With or Without ZOledronic Acid for Patients With HER2- Negative Large Resectable or Locally Advanced Breast Cancer(NEO-ZOTAC).

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2016

At a glance

  • Drugs Zoledronic acid (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms NEO-ZOTAC
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 15 Jul 2014 Status changed to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top